Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced successful completion of a recent pre-New Drug Application (“NDA”) meeting with the Food and Drug Administration (FDA) regarding its govorestat (AT-007) Galactosemia program. Based on discussions with the FDA, the Company believes they are aligned with the FDA and plans to submit an NDA for govorestat (AT-007) for the treatment of Galactosemia in the fourth quarter of this year.
“In the pre-NDA meeting, the FDA expressed their support for a potential NDA based on the govorestat data generated to date in Galactosemia, and provided constructive recommendations for successful NDA acceptance and review,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. “If approved, govorestat will fill an important unmet need for the Galactosemia community. We will work to prepare our regulatory package as expeditiously as possible and expect to submit the NDA to the FDA in the fourth quarter of this year.”
“We thank the FDA for their productive feedback and for their partnership in this process,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “We believe that the clinical efficacy demonstrated to date, combined with galactitol biomarker data and a favorable safety profile, provides us with a solid filing package to the FDA. We are excited to advance towards a regulatory submission for the first potential treatment for Galactosemia.”
https://finance.yahoo.com/news/applied-therapeutics-announces-successful-pre-110000912.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.